Trilogy Capital’s Myovant Sciences Ltd. MYOV Stock Holding History

Trilogy Capital’s Portfolio MYOV Stock Details MYOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,979	Closed	-$226K	–	194
2021 Q1	$226K	Buy	+10,979	New	+$250K	0.02%	148

Other funds holding MYOV

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Trilogy Capital's MYOV Position: Q2 2021 in Review

Trilogy Capital sold out of Myovant Sciences Ltd. (MYOV) in Q2 2021, closing a stake of 10,979 shares — an estimated $226K sold.

Trilogy Capital first reported a position in MYOV in Q1 2021 and held it in 1 quarter. The position peaked at $226K in Q1 2021. 108 funds tracked by Wall St. Rank hold MYOV as of Q2 2021.

Trilogy Capital reported no remaining Myovant Sciences Ltd. position as of Q2 2021 after selling out during the quarter.
Trilogy Capital sold 10,979 Myovant Sciences Ltd. shares in Q2 2021, an estimated $226K.
Trilogy Capital first reported a position in Myovant Sciences Ltd. in Q1 2021 and held it in 1 quarter.
Trilogy Capital's Myovant Sciences Ltd. position peaked at $226K in Q1 2021.
108 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q2 2021.

Based on Trilogy Capital's 13F filing for Q2 2021, filed 14 Jul 2021.